Abstract
Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.
Keywords: Psoriasis area severity index, lymphocyte-function associated antigen-3, memory T cells, Alopecia areata, Quality of life
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Alefacept
Volume: 6 Issue: 3
Author(s): Mustafa Turhan Sahin
Affiliation:
Keywords: Psoriasis area severity index, lymphocyte-function associated antigen-3, memory T cells, Alopecia areata, Quality of life
Abstract: Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.
Export Options
About this article
Cite this article as:
Mustafa Turhan Sahin , Alefacept, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368229
DOI https://dx.doi.org/10.2174/187152307781368229 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Alveolar Capillary Dysplasia: A Lethal Developmental Lung Malformation
Current Respiratory Medicine Reviews Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry How to Measure Pharmacokinetics in Critically Ill Patients?
Current Pharmaceutical Biotechnology Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Pathogenesis in Childhood Idiopathic Nephrotic Syndrome: An Update of Patchwork
Current Pediatric Reviews TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Antibodies Against Recombinant Catalytic Domain of Lethal Toxin of Clostridium sordellii Neutralize Lethal Toxin Toxicity in HeLa Cells
Protein & Peptide Letters Targeted Tumor Therapies at a Glance
Current Drug Targets